CORT Stock: Price, Earnings History and SEC Filings
Corcept Therapeutics Incorporated (CORT) last traded at $81.12, down 5.62% on the latest session and down 29.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.36 against an analyst estimate of $-0.04, a beat of 1000.0%.
$81.12 -5.62%
1 month-29.60%
52-week high$126.38
52-week low$28.66
Volume1.43M
ExchangeNasdaqCM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CORT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 29, 2026 | $0.36 | $-0.04 | +1000.00% |
| Mar 2026 | Apr 30, 2026 | $-0.30 | $-0.30 | +0.00% |
| Dec 2025 | Feb 24, 2026 | $0.20 | $0.27 | -25.93% |
| Sep 2025 | Nov 4, 2025 | $0.16 | $0.18 | -11.11% |
CORT beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for CORT
SEC filing data is not available right now. You can search for CORT on SEC EDGAR.
CORT news
- Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference CallOct 27, 2026 · finance.yahoo.com
- What Corcept Therapeutics Stock Positive Trial Results Mean For ShareholdersOct 26, 2026 · finance.yahoo.com
- Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian CancerOct 26, 2026 · finance.yahoo.com
- Can Corcept Therapeutics Stock Rally 40% After This Dip?Oct 26, 2026 · trefis.com
- Genmab stock surges 9% following positive phase 3 ovarian cancer trial resultsOct 23, 2026 · finance.yahoo.com
- 2 cash-producing stocks to research further and 1 we find riskyOct 22, 2026 · finance.yahoo.com
- 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 DiabetesOct 20, 2026 · finance.yahoo.com
- Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?Oct 19, 2026 · finance.yahoo.com
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated (CORT) is a US-listed public company on Nasdaq.